Responses
Clinical/translational cancer immunotherapy
Original research
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Compose a Response to This Article
Other responses
No responses have been published for this article.
